Skip to main content
Danielle Margalit, MD, Radiation Oncology, Boston, MA, Dana-Farber Cancer Institute

DanielleN.MargalitMD

Radiation Oncology Boston, MA

Head & Neck

Associate Professor of Radiation Oncology, Harvard Medical School Staff Physician, Dana-Farber Cancer Institute and Brigham and Women's Hospital

Dr. Margalit is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Margalit's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical School
    Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2007 - 2011
  • Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical School
    Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2006 - 2010
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2006 - 2007
  • Harvard Medical School
    Harvard Medical SchoolClass of 2006

Certifications & Licensure

  • ME State Medical License
    ME State Medical License 2020 - 2025
  • MA State Medical License
    MA State Medical License 2008 - 2024
  • American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • High Rates of Oropharynx Cancer Tied to HPV
    High Rates of Oropharynx Cancer Tied to HPVSeptember 11th, 2019
  • Estimate of the National Burden of HPV-Positive Oropharyngeal Head and Neck Cancers
    Estimate of the National Burden of HPV-Positive Oropharyngeal Head and Neck CancersAugust 29th, 2019
  • Adding Nivolumab to Standard First-Line Therapy Feasible in Advanced Head and Neck Cancer
    Adding Nivolumab to Standard First-Line Therapy Feasible in Advanced Head and Neck CancerFebruary 20th, 2018

Hospital Affiliations